This approach combines two sources of specificity (TRAIL, TNF-related apoptosis-inducing ligand, which is preferentially active against tumor cells,26 and Kv10.1, which is preferentially expressed in those cells). This evidence concerns the gene TNFSF10 and neoplasm.